Available studies have shown that CXCL1, CXCL5, and CXCL7 levels are significantly elevated in the CSF of NMO patients compared to MS patients and can be used as good bioindicators to differentiate NMO from MS, especially CXCL7 (Liu et al., 2020). This evidence concerns the gene CXCL1 and myeloid sarcoma.